METHODS OF TREATING RESIDUAL BREAST CANCER WITH TRASTUZUMAB EMTANSINE

• 1. 用曲妥珠单抗美坦新治疗残存乳腺癌的方法 [P] . 中国专利： CN112867736A . 2021-05-28
• 2. 用曲妥珠单抗‑MCC‑DM1和帕妥珠单抗治疗早期乳腺癌的方法 [P] . 中国专利： CN106163558A . 2016-11-23
• 3. METHODS OF TREATING RESIDUAL BREAST CANCER WITH TRASTUZUMAB EMTANSINE [P] . EP3856774A1 . 2021-08-04

  机译： 用曲妥珠单抗治疗残留乳腺癌的方法

• 4. METHODS OF TREATING RESIDUAL BREAST CANCER WITH TRASTUZUMAB EMTANSINE [P] . 世界知识产权组织专利： WO2020081119A1 . 2020-04-23

  机译： 曲妥珠单抗氨甲ANS呤治疗残留乳腺癌的方法

• 5. How to treat residual breast cancer with trastuzumab emtansine [P] . KR20210076961A . 2021-06-24

  机译： 如何用曲妥珠单抗治疗残留的乳腺癌

• 1. Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy? [J] . Juan Wu, Rong Kong, Shen Tian, 中国癌症研究（英文版） . 2019,第006期
• 2. HER2 Type Male Breast Cancer Successfully Treated with Pertuzumab, Trastuzumab, and Eribulin Therapy: A Case Report [J] . Masahiro Kitada, Shunsuke Yasuda, Masahiro Abe, 癌症治疗（英文） . 2020,第003期
• 3. Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study [J] . Wei Zhao, Li Bian, Tao Wang, 中国癌症研究（英文版） . 2020,第003期
• 4. LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients [J] . Iwamoto Noriko, Shimomura Akihiko, Tamura Kenji, Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis . 2017,第期
• 5. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [J] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, Breast cancer . 2019,第4期
• 6. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study [J] . Huang Chiun-Sheng, Yang Youngsen, Kwong Ava, Breast cancer research and treatment. . 2021,第3期
• 7. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019
• 8. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019
• 9. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, -1
• 10. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer [O] . Javier Cortés, Véronique Diéras, Sylvie Lorenzen, 2020

• 1. Novel Methods in the Study of the Breast Cancer Genome: Towards a Better Understanding of the Disease of Breast Cancer [J] . Jian Li ,Xue Lin ,Nils Brünner . 癌症治疗（英文） . 2012,第5期
• 2. Ipsilateral breast tumor recurrence in early stage breast cancer patients treated with breast conserving surgery and adjuvant radiation therapy: Concordance of biomarkers and tumor location from primary tumor to in-breast tumor recurrence [J] . Juhi M Purswani ,Fauzia Shaikh ,S Peter Wu . 世界临床肿瘤学杂志：英文版 . 2020,第1期
• 3. 氨甲碟呤供体预处理对致敏大鼠移植心脏存活影响实验研究 [C] . (Missing) ,李跃华 ,宋惠民 . 中国铁道学会全国铁路首届胸心外科学术会议 . 1998
• 4. 白仙风汤剂配合甲氨碟呤治疗类风湿性关节炎急性期的研究 [A] . 罗东东 . 2010